Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains. 

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

COVID does not appear to be a driving factor, and letters are split almost equally between clinical and quality concerns.

With a virtual visit to SciVac in Israel, a belated Revance site inspection in California and two weeks at a Dr. Reddy’s site in India, the US FDA finds ways to overcome travel restrictions in its efforts to oversee drug manufacturing quality.